We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avanir’s Nuedexta First Drug Approved for Pseudobulbar Affect
Avanir’s Nuedexta First Drug Approved for Pseudobulbar Affect
November 5, 2010
The FDA has approved Avanir Pharmaceuticals’ Nuedexta, formerly Zenvia, as the first treatment approved in the U.S. for pseudobulbar affect (PBA).